Serum neurofilament light levels were higher in critically ill patients who had SARS-CoV-2 infection than in those who didn’t, suggesting COVID-19 may contribute to neuronal damage. (Annals of Neurology)
Nursing home residents with COVID-19 had higher 30-day mortality if they also had moderate or severe cognitive impairment, versus the cognitively intact. (JAMA Internal Medicine)
A large-scale global study will investigate relationships between COVID-19 and cognitive decline, Alzheimer’s disease, and other dementia in later life. (Alzheimer’s & Dementia)
A phase III trial of the GLP-1 analogue semaglutide in early Alzheimer’s disease will start this year, Novo Nordisk announced.
Why have drug overdose deaths spiked during the pandemic? PBS‘s “News Hour” takes a look.
A nanoparticle platform penetrated the blood-brain barrier and delivered small interfering RNA (siRNA)–based treatment to mice with traumatic brain injury. (Science Advances)
Direct-to-consumer Alzheimer’s blood tests bring three challenges to the forefront: healthcare system burden, discrimination, and stigma. (JAMA Neurology)
No association was found between copy numbers of survival motor neuron genes SMN1 or SMN2 and risk of ALS or ALS disease severity. (Annals of Neurology)
Parkinson’s disease was associated with decreased retinal microvascular perfusion and structural choroidal changes, further supporting retinal imaging as a potential Parkinson’s biomarker. (JAMA Ophthalmology)
Spatial constraints and cognitive fatigue appeared to impair motor imagery — the mental simulation of an activity — in people with MS. (Scientific Reports)
College football players in a survey underestimated their concussion risks, raising concerns about informed participation. (JAMA Network Open)
Some questions raised in 1920 still baffle neuroscientists. (Discover)